KR20210132003A - 변형된 오르토폭스 바이러스 벡터 - Google Patents

변형된 오르토폭스 바이러스 벡터 Download PDF

Info

Publication number
KR20210132003A
KR20210132003A KR1020217022872A KR20217022872A KR20210132003A KR 20210132003 A KR20210132003 A KR 20210132003A KR 1020217022872 A KR1020217022872 A KR 1020217022872A KR 20217022872 A KR20217022872 A KR 20217022872A KR 20210132003 A KR20210132003 A KR 20210132003A
Authority
KR
South Korea
Prior art keywords
nucleotide sequence
transgene
promoter
nucleic acid
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020217022872A
Other languages
English (en)
Korean (ko)
Inventor
존 씨. 벨
마이클 에스. 허
매튜 와이. 탕
애드리안 펠린
캐롤라인 제이. 브라이트바흐
마이클 에프. 버지스
스티븐 에이치. 번스타인
Original Assignee
오타와 하스피털 리서치 인스티튜트
턴스톤 바이오로직스 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 오타와 하스피털 리서치 인스티튜트, 턴스톤 바이오로직스 코포레이션 filed Critical 오타와 하스피털 리서치 인스티튜트
Publication of KR20210132003A publication Critical patent/KR20210132003A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020217022872A 2018-12-21 2019-12-20 변형된 오르토폭스 바이러스 벡터 Ceased KR20210132003A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862784372P 2018-12-21 2018-12-21
US62/784,372 2018-12-21
US201962872699P 2019-07-10 2019-07-10
US62/872,699 2019-07-10
US201962930524P 2019-11-04 2019-11-04
US62/930,524 2019-11-04
PCT/CA2019/051899 WO2020124274A1 (en) 2018-12-21 2019-12-20 Modified orthopoxvirus vectors

Publications (1)

Publication Number Publication Date
KR20210132003A true KR20210132003A (ko) 2021-11-03

Family

ID=71100021

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020217022872A Ceased KR20210132003A (ko) 2018-12-21 2019-12-20 변형된 오르토폭스 바이러스 벡터
KR1020217022871A Ceased KR20210132002A (ko) 2018-12-21 2019-12-20 변형된 오르토폭스 바이러스 벡터

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217022871A Ceased KR20210132002A (ko) 2018-12-21 2019-12-20 변형된 오르토폭스 바이러스 벡터

Country Status (18)

Country Link
US (2) US20220380799A1 (https=)
EP (2) EP3898997A4 (https=)
JP (2) JP2022516006A (https=)
KR (2) KR20210132003A (https=)
CN (2) CN113661246A (https=)
AU (2) AU2019410148A1 (https=)
BR (2) BR112021012078A2 (https=)
CA (2) CA3124287A1 (https=)
CL (1) CL2021001646A1 (https=)
CO (1) CO2021009354A2 (https=)
EC (1) ECSP21053474A (https=)
IL (2) IL284180A (https=)
MX (2) MX2021007439A (https=)
PE (1) PE20212307A1 (https=)
PH (1) PH12021551436A1 (https=)
SG (1) SG11202106460XA (https=)
TW (1) TW202039851A (https=)
WO (2) WO2020124274A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3778881A1 (en) 2016-01-08 2021-02-17 Replimune Limited Modified oncolytic virus
US12350303B2 (en) 2017-02-03 2025-07-08 University of Pittsburgh—of the Commonwealth System of Higher Education Oncolytic virus therapy
MX2020007010A (es) 2018-01-05 2020-12-10 Ottawa Hospital Res Inst Vectores modificados de orthopoxvirus.
WO2021102307A1 (en) * 2019-11-20 2021-05-27 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Vaccinia viruses and methods for using vaccinia viruses
JP6915792B1 (ja) * 2020-10-01 2021-08-04 国立大学法人鳥取大学 広範囲遺伝子欠損を有する腫瘍溶解性ワクシニアウイルス
WO2023106839A1 (ko) * 2021-12-07 2023-06-15 재단법인 아산사회복지재단 Il-12를 발현하는 재조합 백시니아 바이러스 및 이의 용도
AU2023207821A1 (en) * 2022-01-17 2024-09-05 Nouscom Ag Recombinant orthopox viral vector encoding immunostimulatory proteins for cancer treatment
CN119677861A (zh) * 2022-06-10 2025-03-21 特兰斯吉恩股份有限公司 表达白介素-12的重组病毒
CA3260631A1 (en) * 2022-07-08 2024-01-11 Viromissile, Inc. Oncolytic and recombinant vaccine viruses and their methods of use
KR20250044313A (ko) * 2022-07-27 2025-03-31 아스트라제네카 아베 Pd-1/pd-l1 저해제와 인터루킨-12를 발현하는 재조합 바이러스의 조합물
CN115947797B (zh) * 2022-08-02 2024-07-05 青岛硕景生物科技有限公司 猴痘病毒重组抗原及其应用
WO2024130212A1 (en) 2022-12-16 2024-06-20 Turnstone Biologics Corp. Recombinant vaccinia virus encoding one or more natural killer cell and t lymphocyte inhibitors
CN115927215B (zh) * 2023-01-18 2025-10-17 中国医学科学院病原生物学研究所 一种定向减毒的痘苗病毒疫苗
CN116200349A (zh) * 2023-01-18 2023-06-02 中国医学科学院病原生物学研究所 一种基于改良痘苗病毒天坛株的新型冠状病毒疫苗
CN118240879A (zh) * 2023-11-01 2024-06-25 上海市重大传染病和生物安全研究院 骨架质粒、重组质粒以及猴痘病毒颗粒和应用
WO2026047314A1 (en) * 2024-08-28 2026-03-05 University Of Surrey Recombinant vector

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0992584A3 (en) * 1993-05-19 2000-06-07 Schering Corporation Purified mammalian FLT3 ligands and agonists and antagonists thereof
EP2269619A1 (en) * 2002-08-12 2011-01-05 Jennerex Biotherapeutics ULC Methods and compositions concerning poxviruses and cancer
US20040247578A1 (en) * 2002-10-15 2004-12-09 University Of Pittsburgh Of Commonwealth System Of Higher Education Methods and reagents for inducing immunity
CA2705869C (en) * 2007-11-19 2012-10-30 Philippe Erbs Poxviral oncolytic vectors
DK3036329T3 (da) * 2013-08-22 2021-01-11 Univ Pittsburgh Commonwealth Sys Higher Education Immunonkolytiske terapier
DK3169341T3 (da) * 2014-07-16 2019-08-05 Transgene Sa Onkolytisk virus til ekspression af immun-checkpoint-modulatorer
CN106520778A (zh) * 2015-09-09 2017-03-22 北京锤特生物科技有限公司 改造的白介素12及其在制备治疗肿瘤的药物中的用途
WO2018049261A1 (en) * 2016-09-09 2018-03-15 Icellhealth Consulting Llc Oncolytic virus expressing immune checkpoint modulators
MX2020007010A (es) * 2018-01-05 2020-12-10 Ottawa Hospital Res Inst Vectores modificados de orthopoxvirus.

Also Published As

Publication number Publication date
CA3124301A1 (en) 2020-06-25
JP2022514420A (ja) 2022-02-10
BR112021012078A2 (pt) 2021-08-31
IL284180A (en) 2021-08-31
CO2021009354A2 (es) 2021-11-19
EP3898998A1 (en) 2021-10-27
EP3898997A1 (en) 2021-10-27
WO2020124273A1 (en) 2020-06-25
AU2019404639A1 (en) 2021-08-12
EP3898998A4 (en) 2022-10-05
CL2021001646A1 (es) 2022-02-18
KR20210132002A (ko) 2021-11-03
WO2020124274A1 (en) 2020-06-25
MX2021007439A (es) 2021-08-05
PE20212307A1 (es) 2021-12-10
EP3898997A4 (en) 2022-11-16
CN113661246A (zh) 2021-11-16
US20220380799A1 (en) 2022-12-01
US20220056480A1 (en) 2022-02-24
TW202039851A (zh) 2020-11-01
PH12021551436A1 (en) 2021-12-06
CA3124287A1 (en) 2020-06-25
SG11202106460XA (en) 2021-07-29
AU2019410148A1 (en) 2021-08-12
BR112021011730A2 (pt) 2021-08-31
ECSP21053474A (es) 2021-11-18
CN113454231A (zh) 2021-09-28
JP2022516006A (ja) 2022-02-24
MX2021007438A (es) 2021-09-21
IL284188A (en) 2021-08-31

Similar Documents

Publication Publication Date Title
KR20210132003A (ko) 변형된 오르토폭스 바이러스 벡터
KR102357051B1 (ko) 신규 유전자 재조합 백시니아 바이러스
KR102557818B1 (ko) 키메라 폭스바이러스 조성물 및 이의 용도
KR102243727B1 (ko) 유전자 표적화 및 형질 스태킹을 위한 조작된 트랜스진 통합 플랫폼 (etip)
KR102700586B1 (ko) Hbv 백신
CN108138122B (zh) 免疫调控
AU2017353868B2 (en) Synthetic chimeric poxviruses
TWI902763B (zh) 基於重組痘病毒之抗SARS-CoV-2病毒疫苗
CN114555793B (zh) 基于基因i177l缺失的新型非洲猪瘟减毒活疫苗的开发
JP2026041921A (ja) 合成改変ワクシニアアンカラ（ｓＭＶＡ）ベースのコロナウイルスワクチン
KR101234062B1 (ko) 림프구 내 유전자 도입용 재조합 바이러스 벡터
KR20220148823A (ko) 천연 또는 합성 dna에 의해 생산된 폭스바이러스-기반 벡터 및 그의 용도
CN112243377A (zh) 用于治疗和预防细菌相关的癌症的噬菌体
KR20200131863A (ko) 암 면역요법을 위한, 면역 관문 차단을 발현하는 종양용해 백시니아 바이러스
CN111107872A (zh) 有用于癌症免疫疗法的牛痘病毒突变体
KR20230136600A (ko) 안정적인 세포주에서 효율적인 성장을 가능하게 하는아프리카 돼지 열병 백신의 게놈 결실
KR20200003039A (ko) 표적화된 유전자 파괴 방법 및 면역원성 조성물
CN112261951A (zh) 包含合成嵌合痘苗病毒的干细胞及其使用方法
JP2001292771A (ja) アブラムシ共生バクテリアのゲノムｄｎａ
HK40078138A (en) Poxvirus-based vectors produced by natural or synthetic dna and uses thereof
HK40042130A (en) Stem cells comprising synthetic chimeric vaccinia virus and methods of using them
HK40095569A (zh) 基於重组痘病毒的抗sars-cov-2病毒疫苗
HK40000936B (zh) 新型基因重组牛痘病毒
HK40000936A (en) New genetically-modified vaccinia virus
HK40042802A (en) Bacteriophage for treatment and prevention of bacteria-associated cancers

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

B15 Application refused following examination

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601